Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, well, good luck with that. Doing what you suggest is what drives traders (dumb ones) to a gofundme campaign.
RXMD......can not keep a good company down. And this is a GOOD company.
That's just one of MANY items positive going on here!
WOW! Just WOW!
Cant wait to see our CBD LINE I'LL be the first to order
L2 sure has them .40's building up.....
People who bought on the dip are happy campers this morning
good morning la. That upgrade made my day - couldn't have come at a better time - you can see this rallying ahead right now.
Let's see a little run here!
wow BAD info- no retail shorting on OTC
So you sold Doc..?
Do you have a re-entry pps now..?
Looks like RXMD is headed up again...
Green, green, green, chah, ching,
Explain how to short this.
That was BEFORE the upgrade today and looking forward to Monday. The bar is set a little higher now. Looking to challenge .20 again soon - possibly today.
Looking at time and sales it appears they are filling a large order for someone at .182. Buying just lower and filling there. Now it's filled and up we go until they try and fill the next large order. My estimate is we may push in to the .19's today and close around .185. Perfect consolidation.
Edit. Wow. This may go higher then yesterdays high before pulling back a little. Buying pressure is insane right now. Some orders are coming in over the ask just to get quantity.
Agreed See Thru is leaving out some important revenue streams that are in the works and will contribute significantly to the value here. But I guess they can only report on what is happening today, and not what’s coming tomorrow.
not if but when we get palm beach that will be equal to 5 or more avg locations
Ever yesterday's fiasco i think today's goal is keep it above .15 and close above .17 and it will be a great day.
Good analysis and thank you, but keep in mind out-of-state expansion as well. Two brick and mortars will obviously increase revenues, but what could be done with out-of-state licenses expansion needs to be considered as well.
That's adorable. Please short RXMD. Please. :)
i smoke shorts
Open a short position, cover. Ride a few more pump and dumps. Rinse and repeat until this is back to where this little pharmacy belongs at 2 cents.
Yup JQ - see through equity is a day late a a DOLLAR SHORT here on this price target, lol. Literally a dollar short!
Great News! $.35 price target! But important to point out this does not include or mention the additional new location. Only mentions the out-of-state licenses expansion. Which makes sense since we dont officially have that location yet. Good luck investors.
I agree soup......see through equity has always been too conservative in their price targets if you ask me. A .50 cent price target would have been more in line with where we’re headed.
Thanks and good morning.
.35 target without mention of the new store. could be better but I won't complain.
Well I see seethru has finally come to the same conclusion I came to of .35 pps two weeks ago and again that is based on probable 2017 numbers to be confirmed 03/31.
The valuation will go to over .50 when new acquisition is confirmed and a dollar by year end for certain but of course all IMO
This is intriguing to me: “We are increasing our price target for RXMD at this time to $0.35 per share. Shares eclipsed our prior target of $0.10, as the company has continued to grow and execute in a challenging and competitive environment since our last update....”
RXMD didn’t just eclipse the .10 target, they blew right thru it! If history repeats itself, we should be sitting at or near $.50 soon. IMHO
Geaux RXMD
Good News Today by SeeThruEquity!
( RXMD ) SeeThruEquity Issues Update on Progressive Care, Inc.
8:16 AM ET 3/9/18 | Dow Jones
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Progressive Care, Inc. (OTCQB: RXMD).
The report is available here: RXMD June 2016 Update.
Progressive Care, Inc. (OTCQB: RXMD, "Progressive Care") is a health services and technology company based in Miami, FL. Through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, the company provides a range of health services including administration and practice management, utilization management, quality assurance, Electronic Health Records (HER) EHR implementation, billing and coding, health practice risk management, prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long-term care facilities. The company also provides tele-pharmacy services under the name Tele-Pharmco.
Highlights from the update include:
-- Progressive Care has taken significant strides since the last update
issued by SeeThruEquity on the company, with the business eclipsing $20mn
in revenues in 2017 and several new initiatives intended to drive growth
and improve operations in the future. Highlights include:
Increasing price target to $0.35 for RXMD
We are increasing our price target for RXMD at this time to $0.35 per share. Shares eclipsed our prior target of $0.10, as the company has continued to grow and execute in a challenging and competitive environment since our last update, with 2016 revenues of $18.3mn and 2017 revenues confirmed at above $20mn by the company in January. In the interim, the company has achieved multiple corporate objectives, including an uplisting to the OTCQB and the resumption of plans to expand its pharmacy operations to additional states. We see RXMD as an attractive growth story in the healthcare sector applying an innovative approach to the pharmacy business. It is also worth pointing out that healthcare and related companies offer some shielding against factors affecting the broader markets - given the important role of regulation and industry-specific. We would think this would be true for RXMD as well, if it is able to continue to execute on its business objectives and show continued growth.
Please review important disclosures at www.seethruequity.com.
About Progressive Care, Inc.
Progressive Care, Inc. (OTCQB: RXMD, "Progressive Care") is a health services and technology company based in Miami, FL. Through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, the company provides a range of health services including administration and practice management, utilization management, quality assurance, Electronic Health Records (HER) EHR implementation, billing and coding, health practice risk management, prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long term care facilities. The company also provides tele-pharmacy services under the name Tele-Pharmco.
For more information, please visit the company's website at www.progressivecareus.com.
About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.
Contact:
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity
> Dow Jones Newswires
March 09, 2018 08:16 ET (13:16 GMT)
Thanks - Solid Explanations are Helpful, I'm Still Learning
These types of posts, from a number of folks on the board, are what I really hope to see during the week...
It's great to see people cheering the stock on, but I really appreciate the valuable advice, insight, and trading knowledge I am receiving.
So, thanks to all!
LOL - Guess the Dr. sold a little too soon haha.
Nice to wake up in the morning and get a little upgrade bump!!
Keep rocking everyone -- over .20 next week is a given.
I don't base my trades on anyone else. I rely on TA and Fundamentals. I mostly invest in QB's or higher occasionally investing in a pink that has reported they are in the process of auditing and usually not on the announcement they are just commencing audits. Audits take time. That said:
RXMD has revenue. They have increasing revenue QOQ. Looking at last 10Q they diluted a measly 937.5K shares since Dec. 2016 which tells me they no longer have to rely on selling shares to fund operations. Those shares were from consulting as well not to fund daily business operations.
As far as a trading group leaving? Big deal. Happens all the time. What happened when they were done selling is the key element here. Bulls pushed it right back up to a close just below the upper bollinger and if you look at the daily chart that is exactly where this stock has consistently moved up from.
Looking at the run I see two spinning top candles each followed by a continuation of the run. Those are consolidation candles. Being a Friday I expect we may see another today but that's just a guess. This stock is strong as noted by the push back up yesterday after the exit.
I have also been noticing that general pullbacks are followed by larger and stronger buys. That also tells me mm's may be filling larger orders for people with deep pockets who have the clout and cash to call their broker and say " I want 400K shares but I won't pay market". The mm will then walk it down in small block trades, causing further momentum down as retailers sell, until he has accumulated enough to fill his clients order. Then he buys pushing it back up. After those declines I have seen orders come through ranging from 50K to 400K.
I can tell you this. IHUB is not the major force pushing this up. It's coming from the outside. As far as $1.00 per share? Not going to happen tomorrow or in the weeks to come. 2 pharmacies by my calculation, and others, have this around .40 to .60 cents. They will need two more to reach $1.00+ comfortably. My estimate on two stores is based on the second pharmacy... eventually reaching the $22m mark in revenue. That won't be instantaneous. It will have to grow like the first pharmacy had to grow. Two more pharmacy acquisitions and this is indeed a $1.00+ to $1.50+ stock.
Please no more talk of an R/S to reach the NASD. Once profitability comes in quantity there are other options like stock buybacks with surplus cash on hand. Besides there are plenty of NASD stocks with 300m+ O/S's that are trading in multiple dollars. Their A/S is 500m yet as stated they only sold 937.5K to the market last year. That's peanuts compared to other stocks.
Today I would like to see another spinning top candle with the body right in the middle of yesterdays candle and good consolidation. That would push the following days upper bollinger above the PPS and keep RSI respectably in the mid to low 80's. Enough room for another two maybe three days of upward price movement well into the mid to high .20's before it overheats again and needs more consolidation.
Just my .02 worth.
So we had some folks sale yesterday .20 to .16 and today we have a new target price of .35 Did I MISS SOMETHING...
LOVE THIS!
the company has continued to grow and execute in a challenging and competitive environment!
Again our CEO is swimming with sharks and taking no prisoners this woman could be PRESIDENT
3/9/2018 SeeThruEquity Increasing price target to $0.35 for RXMD
Nothing wrong with that I KNOW few peeps would love to hold
10,000 buy if ya can hold what ya got....
GREAT UPDATE!
ACCESSWIRE ACCESSWIRE•March 9, 2018
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Progressive Care, Inc. (RXMD).
The report is available here: RXMD June 2016 Update.
Progressive Care, Inc. (OTCQB: RXMD, "Progressive Care") is a health services and technology company based in Miami, FL. Through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, the company provides a range of health services including administration and practice management, utilization management, quality assurance, Electronic Health Records (HER) EHR implementation, billing and coding, health practice risk management, prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long-term care facilities. The company also provides tele-pharmacy services under the name Tele-Pharmco.
Highlights from the update include:
Progressive Care has taken significant strides since the last update issued by SeeThruEquity on the company, with the business eclipsing $20mn in revenues in 2017 and several new initiatives intended to drive growth and improve operations in the future. Highlights include:
RXMD reported revenues of $20mn for the full year 2017, representing an increase of 9% over $18.3mn in 2016.
Management reported that it is off to a strong start to 2018, with record prescriptions filled in January, generating $1.8mn in revenues.
RXMD renewed efforts to expand its presence as its PharmCo unit filed applications to operate in Arizona, Rhode Island, and Utah. PharmCo now has 13 states.
RXMD has also resumed plans to add complementary and accretive acquisitions to drive growth. The company announced on March 1, 2018, that it had executed a letter of intent to acquire a pharmacy based in Palm Beach, FL, which will increase its delivery area and solidify its presence in the Palm Beach market and surrounds.
On February 15, 2018, RXMD announced that it had integrated BitCoin payments into its retail pharmacy unit, which will allow customers to choose to pay using BitCoin in a similar payment process as customers using credit cards or PayPal.
RXMD uplisted shares to the OTCQB Venture Market in December 2017, as management executed on this goal set during 2016.
RXMD hired Mass Ventures Corp. to enhance its digital presence and technology including social media, website enhancement, search optimization, and developing an e-commerce platform capable of accepting cryptocurrencies.
Increasing price target to $0.35 for RXMD
We are increasing our price target for RXMD at this time to $0.35 per share. Shares eclipsed our prior target of $0.10, as the company has continued to grow and execute in a challenging and competitive environment since our last update, with 2016 revenues of $18.3mn and 2017 revenues confirmed at above $20mn by the company in January. In the interim, the company has achieved multiple corporate objectives, including an uplisting to the OTCQB and the resumption of plans to expand its pharmacy operations to additional states. We see RXMD as an attractive growth story in the healthcare sector applying an innovative approach to the pharmacy business. It is also worth pointing out that healthcare and related companies offer some shielding against factors affecting the broader markets - given the important role of regulation and industry-specific. We would think this would be true for RXMD as well, if it is able to continue to execute on its business objectives and show continued growth.
Please review important disclosures at www.seethruequity.com.
About Progressive Care, Inc.
Progressive Care, Inc. (OTCQB: RXMD, "Progressive Care") is a health services and technology company based in Miami, FL. Through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, the company provides a range of health services including administration and practice management, utilization management, quality assurance, Electronic Health Records (HER) EHR implementation, billing and coding, health practice risk management, prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long term care facilities. The company also provides tele-pharmacy services under the name Tele-Pharmco.
For more information, please visit the company's website at www.progressivecareus.com.
$RXMD nice to start with $0.35 .....wait for e few dollars in a few years. I stop with working !
Awesome!! More and more exposure for RXMD
I know , right ,
I have made more money with this stock ( and I don't have as many shares as other people ) then I have working my butt off 40hrs a week plus
Waiting for this to show up on IHUB. Could be another fun day here!
RXMD!
( RXMD ) SeeThruEquity Issues Update on Progressive Care, Inc.
8:16 AM ET 3/9/18 | Dow Jones
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Progressive Care, Inc. (OTCQB: RXMD).
The report is available here: RXMD June 2016 Update.
Progressive Care, Inc. (OTCQB: RXMD, "Progressive Care") is a health services and technology company based in Miami, FL. Through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, the company provides a range of health services including administration and practice management, utilization management, quality assurance, Electronic Health Records (HER) EHR implementation, billing and coding, health practice risk management, prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long-term care facilities. The company also provides tele-pharmacy services under the name Tele-Pharmco.
Highlights from the update include:
-- Progressive Care has taken significant strides since the last update
issued by SeeThruEquity on the company, with the business eclipsing $20mn
in revenues in 2017 and several new initiatives intended to drive growth
and improve operations in the future. Highlights include:
Increasing price target to $0.35 for RXMD
We are increasing our price target for RXMD at this time to $0.35 per share. Shares eclipsed our prior target of $0.10, as the company has continued to grow and execute in a challenging and competitive environment since our last update, with 2016 revenues of $18.3mn and 2017 revenues confirmed at above $20mn by the company in January. In the interim, the company has achieved multiple corporate objectives, including an uplisting to the OTCQB and the resumption of plans to expand its pharmacy operations to additional states. We see RXMD as an attractive growth story in the healthcare sector applying an innovative approach to the pharmacy business. It is also worth pointing out that healthcare and related companies offer some shielding against factors affecting the broader markets - given the important role of regulation and industry-specific. We would think this would be true for RXMD as well, if it is able to continue to execute on its business objectives and show continued growth.
Please review important disclosures at www.seethruequity.com.
About Progressive Care, Inc.
Progressive Care, Inc. (OTCQB: RXMD, "Progressive Care") is a health services and technology company based in Miami, FL. Through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, the company provides a range of health services including administration and practice management, utilization management, quality assurance, Electronic Health Records (HER) EHR implementation, billing and coding, health practice risk management, prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long term care facilities. The company also provides tele-pharmacy services under the name Tele-Pharmco.
For more information, please visit the company's website at www.progressivecareus.com.
About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.
Contact:
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity
> Dow Jones Newswires
March 09, 2018 08:16 ET (13:16 GMT)
Still holding my massive 10,000 shares at .17.lol
We got a whole mess of flippers out of the pipes. Easy climb back up now
Yup! I want to see dollars before I sell anything here!
I can live on my salary....
RXMD!
You got that right , I'm not rich , but I will be by holding onto RXMD !!!
Yes, yes we will!, YOUR AWESOMENESS
We are all here to see dollars soon!
DAM LOVE THIS company!...Morning All..I'll take slow and steady.
RXMD MOST READ AND POSTED BOARDS! WELCOME ALL NEWS INVESTORS!
Stickies have sooooooooooooo much information.
2nd year financial audit due end of March!
2018 will be an exciting ride!
Followers
|
746
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
194370
|
Created
|
01/09/11
|
Type
|
Free
|
Moderators gedi8 Truth022809 stockforce TrackDude MrMike241 |
Progressive Care Gains SEC Reporting Status
See on website
Miami, FL – April 12, 2022 – Globe Newswire via NewMediaWire – Progressive Care, Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced that, effective April 11, 2022, its Registration Statement on Form 10 filed with the U.S. Securities and Exchange (the “SEC”) to register its shares of common stock under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) became automatically effective.
The effective Form 10 obligates the Company to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act. In addition, management and certain shareholders are subject to the beneficial ownership reporting requirements of Section 13 and 16 of the Exchange Act.
Alan Jay Weisberg, Chairman and Chief Executive Officer of the Company said, “For me, it was always important to have the Company become fully reporting with the SEC. I know how critical it is for individual and institutional investors to have the Company file its financial reports with the SEC as it provides a higher level of confidence in the information reported by the Company and a superior level of transparency. I believe that the Company’s compliance with the Exchange Act will ultimately help drive shareholder value and enable us to access higher quality institutional capital. We remain committed to strong corporate governance and steadfast in pursuit of our journey to Nasdaq.”
To view the Form 10 filling, please click:
https://www.sec.gov/Archives/edgar/data/0001402945/000149315222009357/form10-12ga.htm
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at $38.9 million
- COVID-19 testing revenue of approximately $4.3 million
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million
• Gross margin increased to 26% in 2021, from 23% in 2020
• EBITDA increased to $167,000 in 2021 from $7,000 in 2020
• Cash balance of $1.4 million as of December 31, 2021
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021
• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021
PRODUCTS AND SERVICES
Advances in HIV/AIDS treatment has greatly increased the ability of those suffering from the disease to manage their symptoms and live longer, healthier lives. Effective management of the disease begins with taking the right medications with the right dose at the right times. For those in the HIV/AIDS community, adhering to the very strict dietary and medicinal requirements can be extremely difficult. Normal activities are often interrupted and sometimes prevented by the struggle to be in compliance.
PharmCo wants to ease this burden on those impacted by this life altering disease. We aim to make compliance with prescription regiments as easy as possible. By understanding the sensitive nature of HIV/AIDS and the needs of those afflicted, PharmCo provides the following services to patients with these special needs:
1. Confidential packaging
2. Packaging tailored to suit a patient's individual life style
3. Free delivery from a variety of sources including PharmCo's proprietary delivery fleet
4. A staff that is well trained in acute illnesses, who understands the patient's needs and
concerns
5. 24 hour emergency support
6. Timely availability of specialty medications due to our extensive inventory
7. Access to newly developed medications
PharmCo is a fully accredited DME supplier. In November 2010, as part of Medicare's competitive bidding, PharmCo was awarded a three year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. PharmCo carries an extensive inventory of equipment and accessories with most special requests being honored with same day or next day delivery. The company offers both sales and rentals with size, color, style, and brand options available on the majority of products. Most importantly, the staff is knowledgeable, helpful and dedicated to providing superior customer service.
PharmCo offers home service and maintenance, defective product replacements, and free home installation and instruction.
PharmCo's institutional clients have come to depend on the company's proven accuracy, dispensing methods, and immediate response time. With PharmCo compliance and efficiency assistance, long term care institutions are able to provide the highest level of continued care to their patients. PharmCo provides purchasing, repackaging and dispensing of both prescription and non-prescription pharmaceutical products. PharmCo utilizes a unit-of-dose packaging system as opposed to traditional vials used for its retail customers. This method of distribution improves control and patient compliance with recommended drug therapy by increasing the timeliness and accuracy of medication dispensing. PharmCo also provides computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Its consulting services consist primarily of evaluation of monthly patient drug therapy and monitoring the institution’s drug distribution system.
Long term care institutions can count on PharmCo for the following services:
1. On time, same day deliveries available twice a day with 24 hour emergency support
2. Language assistance in English, Spanish, French, Creole, Portuguese, Russian, and Hebrew
3. Unit-dose packaging options tailored the facility's needs
4. Prescription data accuracy
5. Extensive medication and DME inventory
6. Access to OTC medications, nutritional products and personal hygiene items
7. Provision and review of medication carts
8. Monthly pharmacy consultations- drug interactions, redundant therapies, side effects, etc.
9. Compliance updates and consultations
10. Staff Training
11. Exceptional customer service.
Toll Free: 888-919-7411 Phone: 305-919-7399 Fax: 305-919-7424
HOURS
Monday- Thursday 8:30 AM - 6:30 PM
Friday 8:30 AM - 6:00 PM
Saturday 11:00 AM - 4:00 PM
PharmCo currently services: Miami-Dade, Broward, Palm Beach, Martin, and St. Lucie Counties.
Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in RevenueGLOBENEWSWIRE – 11:16 AM ET 03/29/2022 |
Progressive Care’s PharmcoRx Gains Status as Approved COVID-19 Test Vendor in the U.S. for Travel to Beijing Winter Olympic Games in ChinaGLOBENEWSWIRE – 7:00 AM ET 02/02/2022
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |